8-K: Inogen Reports Q3 2025 Results, Raises EBITDA Outlook

Inogen, Inc. announced its third quarter 2025 financial results, reporting 4.0% revenue growth and raising its full-year adjusted EBITDA guidance.

Summary

• Total revenue reached $92.4 million, a 4.0% year-over-year increase, marking the seventh consecutive quarter of mid-single-digit growth.
• GAAP net loss was $5.3 million, an improvement from $6.0 million in the prior-year period.
• Adjusted net loss was $0.5 million, an improvement from $2.6 million in the prior-year period.
• Adjusted EBITDA was $2.3 million, up from $0.5 million in the prior-year period, marking the third consecutive quarter of positive adjusted EBITDA.
• Generated $2.2 million in positive operating cash flow, increasing quarter-end cash, cash equivalents, marketable securities, and restricted cash to $124.5 million.
• Reiterated full-year 2025 revenue outlook of $354 million to $357 million and raised adjusted EBITDA guidance to approximately $2 million.
• Initiated a limited market release of the Simeox airway clearance device in the United States.

Sentiment

Score: 7

Explanation: The company demonstrated consistent revenue growth, significantly improved adjusted EBITDA, and positive operating cash flow. While still reporting a net loss, the improvements and raised EBITDA guidance indicate a positive trajectory and effective cost management, partially offset by declines in direct-to-consumer sales and gross margin.

Positives

• Achieved seventh consecutive quarter of mid-single-digit revenue growth (4.0% year-over-year to $92.4 million).
• Reported $2.3 million in adjusted EBITDA, marking the third consecutive quarter of positive adjusted EBITDA, significantly up from $0.5 million in the prior-year period.
• Generated $2.2 million in positive operating cash flow.
• Strengthened cash, cash equivalents, marketable securities, and restricted cash to $124.5 million with no debt outstanding.
• GAAP net loss improved to $5.3 million from $6.0 million year-over-year.
• Adjusted net loss improved to $0.5 million from $2.6 million year-over-year.
• Successfully initiated a limited market release of the Simeox airway clearance device in the United States.
• Raised full-year adjusted EBITDA guidance to approximately $2 million.
• Total operating expense decreased by 1.4% to $48.4 million, reflecting ongoing cost management efforts.
• Business-to-business domestic sales increased by 6.6% to $24.884 million.
• Business-to-business international sales increased by 18.8% to $38.403 million.
• Units sold increased to 51,100 from 43,900 in the prior-year period.

Negatives

• GAAP net loss of $5.3 million and adjusted net loss of $0.5 million for the quarter.
• Total gross margin decreased to 44.7% from 46.5% in the prior-year period, primarily due to increased business-to-business sales as a percentage of total revenue.
• Direct-to-consumer domestic sales decreased by 17.9% to $15.803 million.
• Direct-to-consumer domestic rental revenue decreased by 4.4% to $13.300 million.
• Net rental patients decreased to 50,000 from 51,400 as of period-end.
• Incurred one-time legal and settlement expenses of $1.8 million.

Risks

• Risks and uncertainties relating to Inogen's fourth quarter and full year financial guidance.
• Market acceptance of its products.
• Competition in the medical technology industry.
• Capabilities of its sales, marketing, and distribution networks.
• Planned sales, marketing, and research and development activities.
• Risks associated with international operations.

Future Outlook

Inogen is reiterating its full-year 2025 revenue outlook in the range of $354 million to $357 million, representing approximately 6% growth at the midpoint compared to 2024. The company is raising its full-year adjusted EBITDA expectations to approximately $2 million. For the fourth quarter of 2025, revenue is expected to be in the range of $87 million to $90 million, reflecting approximately 10% year-over-year growth at the midpoint.

Management Comments

• "We continue to make meaningful progress, driving consistent mid-single-digit revenue growth, operational improvements, and strong adjusted EBITDA."
• "This quarter's results reflect the strength of our commercial strategies, financial discipline, and commitment to delivering innovative solutions."
• "Looking forward, we remain focused on building long-term value for our shareholders by advancing Inogen's leadership in respiratory care."

Industry Context

The filing positions Inogen as a leading global medical technology company in the homecare respiratory products sector. The consistent mid-single-digit revenue growth and positive adjusted EBITDA suggest a stable, albeit competitive, market for respiratory care devices. The introduction of the Simeox airway clearance device indicates ongoing product innovation within the sector.

Comparison to Industry Standards

• The filing does not provide specific comparisons to industry benchmarks, competitors, or projects.

Legal Proceedings

• Incurred one-time legal and settlement expenses of $1.8 million during the third quarter of 2025.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through consistent revenue growth, operational improvements, and positive adjusted EBITDA. Raised EBITDA guidance could be seen favorably.
• Customers: Continued availability of innovative respiratory products, including the new Simeox airway clearance device.
• Employees: Ongoing cost management efforts could imply efficiency drives, but no direct impact on employment levels is stated.

Next Steps

• Host a conference call on November 5, 2025, at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss the financial results.
• Continue to advance Inogen's leadership in respiratory care and build long-term value for shareholders.
• Further develop and market innovative respiratory therapy devices.

Key Dates

Recommendation

Inogen shows mixed signals with consistent revenue growth and improved adjusted EBITDA, indicating operational efficiency and market traction for its B2B segments. However, the company still reports a GAAP net loss, and direct-to-consumer sales and rental revenue are declining, which are areas of concern. The raised EBITDA guidance is positive, but the overall financial picture suggests a "hold" as the company navigates profitability challenges while growing its top line and managing costs. Investors should monitor the sustainability of EBITDA improvements and the performance of new product introductions like Simeox.

Keywords

Inogen, INGN, Financial Results, Q3 2025, Revenue Growth, Adjusted EBITDA, Net Loss, Medical Technology, Respiratory Products, Homecare, Simeox, Guidance